DMTTF 0.06 Small Pharma Inc.
| Range: | 0.045-0.1905 | Vol Avg: | 109353 | Last Div: | 0 | Changes: | -0.01 |
| Beta: | 0.86 | Cap: | 0.04B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Mon Jun 07 2021 | Empoloyees: | |||
| CUSIP: | CIK: | ISIN: | Country: | GB | |||
| CEO: | Mr. George Tziras | Website: | https://www.smallpharma.com | ||||
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. The company's product includes SPL026 Placebo, which is in clinical Phase IIA for the treatment of major depressive disorder. Its preclinical stage programs include SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801 oral formulation of 6-hydroxynorketamin. The company was incorporated in 2015 and is headquartered in London, the United Kingdom.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow